Termination of Product Marketing Collaboration Between Sanofi-Aventis and Chugai in Japan
TOKYO, July 31, 2007-Sanofi-aventis K.K. (hereinafter: "sanofi-aventis", Headquarters: Shinjuku-ku, Tokyo, President: Philippe Fauchet), and Chugai Pharmaceutical Co., Ltd. (hereinafter: "Chugai", Headquarters: Chuo-ku, Tokyo, President: Osamu Nagayama) announced today that the marketing collaboration in Japan for the 7 products of sanofi-aventis currently sold by Chugai will end on December 31, 2007.
The marketing rights for the following 7 products will be returned to sanofi-aventis accordingly: "Acetanol®" (generic name: acebutolol hydrochloride) for the treatment of hypertension, angina, arrhythmia (beta blocker), "Amoban®" (generic name: zopiclone) for sleep disorder, "Cefotax®" (generic name: cefotaxime sodium) a cephem antibiotic, "Preran®" (generic name: trandolapril) an angiotensin-converting enzyme inhibitor, "Benambax®"(generic name: pentamidine isetionate) for carinii pneumonia, "Menamin®" (generic name: ketoprofen) an anti-inflammatory, analgesic, antipyretic drug and "Rythmodan®" (generic name: disopyramide) for arrhythmia.
Net sales for the 7 products totaled 12,926 million yen in Chugai Pharmaceutical fiscal year 2006.
Sanofi-aventis is one of the world's leading pharmaceutical companies, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Chugai Pharmaceutical, specializes in prescription pharmaceuticals and based in Tokyo, is Japan's leading research-based pharmaceutical companies with strengths in biotechnology products.
Since the start of the strategic alliance with Roche in October
2002, Chugai is actively involved in prescription pharmaceutical
R&D activities in Japan and abroad as an important member of
the Roche Group. Specifically, Chugai is working to develop
innovative products with global applications, focusing on the
disease areas of oncology, renal disease, and bone and joint.
In Japan, Chugai's research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is conducting research for technology development for industrial production.
Overseas, Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
External Communication Group
TEL : 03-6301-4148
Chugai Pharmaceutical Co., Ltd.
Corporate Communications Dept.
Corporate Communications Group
TEL : 03-3273-0881
Name of listed company: Chugai Pharmaceutical Co.,
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo
President & CEO: Osamu Nagayama
Inquiries to: Mamoru Togashi
General Manager, Corporate Communications Dept.
Name of Company:
Head office: 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo
President : Philippe Fauchet
Posted: July 2007